Transplant Procurement Tech

Dr. Tue Te receives 5-year NIH grant to investigate early vocal and sleep signals of cognitive decline. Project aims to build a database to screen older adults for Alzheimer's and other dementias through voice and sleepiness signals September 28, 2026 Dr. Tue Te, assistant professor of medicine at the David Geffen School of Medicine at UCLA Health, has been awarded a five-year K23 Career Development Award from the National Institute of Health (NIH)/National Institute on Aging totaling $845,100. Her project, titled "Advancing Early Detection of Mild Cognitive Impairment and Dementia through Digital Biomarkers," will run from September 2026 to May 2031. This project will investigate how spontaneous speech, voice signals, and sleep measures can be used as signals to predict subtle signs of cognitive impairment in real-world clinical settings. "Speech and voice analysis offers a promising, non-invasive tool in medical research," said Te. "We know from our previous research that there is a connection between verbal response time and hidden sleepiness - an important factor in cognitive assessment. By measuring the specific biomarkers between vocal cues and sleep, we can create a scalable approach for the early detection of cognitive decline." Specific aims of this project will be to: assess the feasibility and acceptability of collecting and analyzing spontaneous voice data during outpatient visits; develop machine learning models that use voice and speech features to distinguish mild cognitive impairment from normal cognition; and explore associations between voice features and sleepiness, testing whether voice-based measures predict sleepiness comparable to EEG-based assessments. Book an appointment. See a doctor, virtually or in-person, with our easy online booking options. Articles: Services: Physician. Tue T. Te, MD, MS Pulmonology, Sleep Medicine Media contact. Rocio Cruz

UCLA Health researchers awarded $1.75M grant to study liver toxicity from Duchenne muscular dystrophy treatment. September 24, 2026 UCLA Health researchers have been awarded a $1.75 million federal grant to investigate why some Duchenne muscular dystrophy patients develop liver toxicity after receiving a gene therapy treatment meant to prevent muscle deterioration. Funded by a U.S. Department of Defense grant through 2029, the research will investigate liver toxicity caused by treatment with Elvidys, a one-time gene therapy treatment to help Duchenne muscular dystrophy patients produce a functional version of a missing muscle-protecting protein called micro-dystrophin. One potential side effect of the treatment is liver injury and acute liver failure among some individuals. Duchenne muscular dystrophy is one of the most common genetic diseases of childhood for boys and causes rapid muscle deterioration. The disease causes loss of ambulatory function by age 12, loss of upper arm use in teen years and eventually heart and respiratory failure that leads to death in their 20s. There is no known cure. The new study will be led by UCLA neurologist Dr. Melissa Spencer in collaboration with neurologist Dr. Perry Shieh, Assistant Professor Tayo Ikotun of the Department of Molecular & Medical Pharmacology and Professor Alex Huk of the Department of Psychiatry and Biobehavioral Sciences. They will use biological samples collected from patients before and after treatment to investigate the immune, molecular and physiological responses associated with liver injury and identify factors that may place certain patients at great risk of liver toxicity. The long-term goal of the study is to develop ways to predict, prevent and effectively manage liver toxicity and thereby improve safety of the treatment and other similar gene therapies. Articles: Services: Team member. Melissa Spencer, PhD Media contact. Will Houston

UCLA scientists engineer ready-to-use cancer-fighting T cells for solid tumors. A new stem cell-based platform produces uniform T cells that attack solid tumors two ways while avoiding a dangerous side effect Engineered T cells, designed to recognize and attack tumor cells, illustrating a new approach to developing off-the-shelf cell therapies for solid tumors. Credit: Lili Yang Lab/UCLA September 8, 2026 By Linda Wang Key takeaways. * UCLA researchers have developed a way to mass-produce cancer-fighting T cells from blood stem cells found in cord blood, engineered to target a protein found in many solid tumors - creating uniform batches instead of custom treatments for each patient. * This way, scientists ensure that all the T cells they produce carry the same single tumor-targeting receptor, avoiding the random receptors that can attack healthy tissue and cause a dangerous condition called graft-versus-host disease. * In mouse models of ovarian cancer and melanoma, a single dose kept tumors in check and extended survival, outperforming conventional donor T cells, which caused toxic side effects in the same tests. T cell receptor, or TCR, therapy is a cancer treatment that genetically reprograms immune cells, called T cells, to hunt down cancer with precision. It's similar to another treatment, CAR T-cell therapy, but with one key difference: CAR T-cell therapy can only spot proteins that naturally appear outside of a cancer cell. TCR therapy, however, can also catch small protein fragments from inside the cell, which get carried to the surface and displayed like little name tags. This ability gives TCR therapy access to a much wider range of cancer targets - a big deal for solid tumors, since most of what makes those cells cancerous is hidden inside them, not on the surface. But there's a bottleneck: In currently available approaches, each dose has to be custom-made from a patient's own T cells, a process that can take weeks and cost well into the six figures. Researchers have also explored engineering donor-derived T cells instead, which could be manufactured in advance and used off-the-shelf for many patients, but this method is largely limited because it carries the risk of graft-versus-host disease, a dangerous condition in which transplanted immune cells attack healthy tissues. UCLA scientists have developed an approach that sidesteps both hurdles at once. In a study published in Cell Reports Medicine, the team describes a scalable method for producing uniform batches of cancer-fighting T cells from blood stem cells found in donated cord blood, engineered to recognize a protein found in many solid tumors. In mouse models of ovarian cancer and melanoma, a single dose of these engineered cells, called AlloESO-T cells, kept tumors in check and extended survival without triggering dangerous side effects. "This platform brings us closer to a future where the product is already made, frozen and ready to go as soon as the patient needs," said co-senior author Lili Yang, a professor of microbiology, immunology and molecular genetics and a member of the UCLA Broad Stem Cell Research Center and the UCLA Health Jonsson Comprehensive Cancer Center. Safe by design. Rather than starting with mature, donor-derived T cells, the researchers began a step earlier - with blood stem cells found in cord blood, which naturally give rise to every type of blood and immune cell. They then added a gene for a receptor that targets NY-ESO-1, a protein found in many solid tumors. Fragments of NY-ESO-1 get pushed to the outer surface and displayed there, name-tag style. The researchers then grew these engineered stem cells into T cells in the lab. Introducing that receptor this early keeps the stem cells from developing their own natural receptors as they mature. That matters because conventional donor-derived T-cell therapies start from T cells that already carry a random assortment of natural receptors, which must be silenced with extra gene editing, since any of them could attack the patient's healthy tissue. "Stem cells are undifferentiated - they're not yet mature T cells with a fixed receptor already in place," said co-first author Yichen (John) Zhu, a graduate student in the UCLA Broad Stem Cell Research Center Training Program. "When we differentiate our engineered stem cells into T cells, essentially all of the resulting cells carry the same receptor and go after the same tumor target." Closing the escape hatch on tumor cells. Solid tumors are notorious escape artists, often shedding or hiding the very markers a therapy is built to find. To guard against that, the AlloESO-T cells also carry natural killer cell receptors - a separate detection system - that detect stress signals many tumor cells display on their surface. That gives the therapy a second, backup way to recognize and destroy tumor cells, independent of whether the NY-ESO-1 name tag is present at all. "Solid tumors are very diverse," Zhu said. "Some tumor cells lose or hide the antigen a therapy is designed to find - what we call antigen escape. When that happens, a therapy built around a single target loses its grip. Our stem cell-derived cells still have a second mechanism to kill those tumor cells." In lab tests against human melanoma, ovarian and prostate cancer cells, that backup let the engineered cells destroy tumor cells the main NY-ESO-1 route couldn't catch on its own - closing an escape route that limits many single-target therapies. Controlling tumors, extending survival. In mouse models of ovarian cancer, a single dose led to durable tumor control and extended survival, while a comparison group treated with T cells engineered from mature donor T cells kept the tumors only partially in check and developed graft-versus-host disease. A melanoma model told the same story: The AlloESO-T cells slowed the cancer and delayed its return, while the comparison cells offered only fleeting control. The difference came down to where the cells went. After a single infusion, the AlloESO-T cells multiplied roughly 100-fold, traveled to the tumor, expanded where they were needed and stayed active for weeks - while largely leaving healthy organs alone. In contrast, the conventionally engineered cells spread through the liver and lungs and triggered the toxicity this new approach is designed to avoid. Cheaper to make at massive scale. Perhaps the platform's biggest promise is that it could put T-cell therapies within reach for many more patients. Because the therapy starts from stem cells rather than fully formed T cells collected one patient at a time, manufacturing can run at a scale that custom-made therapies can't match. "From a small number of cord blood stem cells, we can generate trillions of therapeutic cells - enough for thousands of doses - within about six weeks," said co-senior author Yanruide (Charlie) Li, a postdoctoral scholar in the Yang lab. "At an estimated $5,000 per dose, this approach would be far more accessible than today's therapies." One platform to target many solid cancers. Many solid tumors don't carry a good target that naturally appears on their surface for a therapy to grab onto, which leaves those patients with few options. But because this approach uses an engineered T-cell receptor - which recognizes targets that originate inside the tumor cell, displayed as fragments on its surface - it could reach cancers that have been hard to treat. "We're not just presenting one therapy for one target. We want to share the platform itself," Li said. "As long as a receptor for a given cancer antigen has been validated, we can build it into this system and generate T cells specific to that target." This AlloESO-T platform builds on manufacturing groundwork the Yang lab has already laid for its CAR-NKT platform - a related but distinct off-the-shelf immunotherapy approach. The team, which has already partnered with the UCLA Health Center for Advanced Biotherapies to produce clinical-grade cells for that program, expects to draw on that same manufacturing relationship to scale up AlloESO-T, which could help move it toward a clinical trial faster than starting from scratch. Additional authors include Jiaji Yu, Yu Jeong Kim, Yanxin Tian, Zhe Li, Yuning Chen, Zibai Lyu, Enbo Zhu, Annabel S. Zhao, Nathan Ma, Catherine Zhang, Adam Kramer, Matthew Wilson, Ryan Hon, Yu-Chen Wang, Siyu Lin, Xinyuan Shen, Zoe Hahn, Yuchong Zhang and Aijun Wang. The therapeutic cells described in this study have been used in preclinical tests only; it has not been tested in humans in clinical trials or approved by the FDA as safe and effective for use in humans. This research was supported by the California Institute for Regenerative Medicine, the UCLA Molecular Biology Institute, the UCLA Office of the Chancellor and the UCLA Goodman-Luskin Microbiome Center. Articles: Cancer Center member. Media contact. Ani Vahradyan 310-968-6144